AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BCAX
  4. [SCHEDULE 13G/A] Bicara Therapeutics Inc. SEC Filing

[SCHEDULE 13G/A] Bicara Therapeutics Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source:

Stock BCAX logo
Bicara Therapeutics

NASDAQ:BCAX

BCAX Rankings

#4241 Ranked by Market Cap
N/A Ranked by Dividends

BCAX Latest News

Jul 31, 2025
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Jun 3, 2025
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Jun 1, 2025
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
May 22, 2025
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
May 13, 2025
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BCAX Latest SEC Filings

Jul 31, 2025
[SCHEDULE 13G/A] Bicara Therapeutics Inc. SEC Filing
Jul 17, 2025
[SCHEDULE 13G] Bicara Therapeutics Inc. SEC Filing
Jun 18, 2025
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity

BCAX Stock Data

569.36M
43.93M
11.65%
90.04%
10.35%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE